Around the Practice

Panelists discuss how bispecific antibody therapies are revolutionizing multiple myeloma treatment by providing highly effective, accessible options for heavily pretreated patients while addressing key implementation challenges including patient selection, sequencing strategies, safety management protocols, and the transition from academic centers to community-based care delivery.

Jan Drappatz MD; Elizabeth Maher, MD, PhD; Alexandra M. Miller, MD, PhD; and David Reardon, MD discuss how the 2021 WHO classification emphasizing molecular markers like IDH mutations has transformed glioma treatment from a histology-based approach to personalized therapy, with IDH inhibitors offering new first-line options that can defer radiation and chemotherapy while maintaining quality of life for patients with IDH-mutant gliomas.

Samuel Rosner, MD, discusses how the treatment landscape for EGFR-mutated non-small cell lung cancer has evolved from first-generation targeted therapies to osimertinib as the current standard of care, while exploring emerging options like fourth-generation TKIs, antibody-drug conjugates, and bispecific therapies to overcome resistance mechanisms.

Ajai Chari, MD; Ajay Nooka, MD, MPH, FACP; Muhamed Baljevic, MD; Gurbakhash Kaur, MD; and Anupama Kumar, MD, discuss how recent advances in multiple myeloma (MM) treatment, including quadruplet therapy regimens, CAR T-cell therapies in earlier lines, and emerging bispecific antibodies and trispecific agents, are transforming the treatment landscape with the potential to cure rather than just manage the disease, while addressing optimal sequencing strategies and management of adverse events across newly diagnosed and relapsed/refractory (R/R) settings.

Panelists discuss the evolving role of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM), highlighting its transformative impact on patient outcomes across diverse real-world settings, the importance of individualized treatment decisions based on comparative efficacy and toxicity of available therapies, innovative approaches like bridging with bispecific antibodies, strategic sequencing with other B-cell maturation antigen–targeted agents, early integration in the treatment pathway, proactive management of neurotoxicity and infections, expanding access to high-risk populations, and the critical need for collaboration between specialized centers and community providers to optimize patient care and maximize durable responses.

Panelists highlighted evolving personalized treatment strategies in HER2-positive metastatic breast cancer—spanning maintenance therapy innovations, frontline and later-line sequencing with agents like trastuzumab deruxtecan and tucatinib, management of CNS metastases and toxicities such as interstitial lung disease, and the critical role of multidisciplinary care and clinical trials in optimizing patient outcomes and quality of life throughout complex, prolonged disease courses.

Leslie Randall, MD; Marion E. Cole, MD; Asim Farooq, MD, and Mallorie Haba, FNP, discuss how antibody-drug conjugates are transforming treatment strategies in recurrent ovarian cancer by offering new options for patients with platinum-resistant disease, emphasizing molecular testing, treatment sequencing, side effect management—particularly ocular toxicities—and the importance of patient-centered care.

Leading oncology experts come together for an in-depth virtual roundtable on immunotherapy strategies in advanced or metastatic melanoma. Moderated by Dr. Douglas B. Johnson of Vanderbilt University Medical Center, and joined by distinguished panelists Dr. Ahmad Tarhini (Moffitt Cancer Center) and Dr. Yana G. Najjar (University of Pittsburgh Medical Center), the series explores the evolving treatment landscape with a focus on real-world application, efficacy, and patient safety.

Panelists discuss the current treatment landscape of ES-SCLC, review recent clinical trials, and how they prepare their sites for tarlatamab administration, patient monitoring and management of adverse events

Panelists discuss how enhancing diagnostic accuracy, optimizing multidisciplinary care, and advancing treatment strategies—including targeted therapies—can improve outcomes and decision-making in patients with advanced epithelioid sarcoma (ES).

Panelists discuss how the evolving treatment landscape in relapsed/refractory follicular lymphoma, particularly in the third-line setting and beyond, is shaping clinical decision-making through patient-centered strategies that balance efficacy, tolerability, and individualized care.

Jason Efstathiou, MD, DPhil, FASTRO, FACRO; Brandon Mancini, MD, MBA, FACRO; Comron Hassanzadeh, MD, MPH; and Bridget Koontz, MD, FASTRO, discuss the evolving role of PSMA PET imaging in prostate cancer, examining its impact on diagnosis, disease staging, treatment decisions, and posttreatment assessment. They also review key clinical trial data, current guideline recommendations, and real-world applications of PSMA PET imaging in practice.

Krish Patel, MD; Saurabh Dahiya, MD, FACP​; Nathan Denlinger, DO, MS; Mohamed M. Hegazi, MD​, and Samuel Yamshon, MD discuss how, the DLBCL treatment landscape has evolved with CAR-T therapies transforming outcomes in R/R cases. Key considerations include risk stratification, optimal sequencing, and real-world efficacy vs. trial data. Future advances may refine patient selection, enhance manufacturing, and integrate novel therapies for improved durability and safety.

Panelists discuss how a patient-centered approach, shared decision-making, and clear communication between physicians, patients, and caregivers are essential in improving care, treatment adherence, and long-term management for individuals with paroxysmal nocturnal hemoglobinuria (PNH).

This program was made possible with support from Novartis Pharmaceuticals.

Panelists discuss how evolving treatment options, including T-DXd and tucatinib-based regimens, are reshaping the management of HER2+ metastatic breast cancer in later-line settings, emphasizing the importance of personalized therapy and proactive toxicity management.

Panelists discuss how the CAR-T referral process for relapsed/refractory multiple myeloma involves careful patient selection, bridging therapy, and coordination between community and academic centers to optimize treatment outcomes.

Cristina Gasparetto, MD; Amandeep Godara, MBBS; Ken Shain, MD, PhD; and Mansi Shah, MD, examine evolving treatment paradigms in newly diagnosed multiple myeloma (NDMM), highlighting the increasing role of daratumumab-based regimens across the care spectrum—from induction through maintenance—supported by landmark trials like PERSEUS, CASSIOPEIA, and AURIGA that demonstrate improved outcomes with these approaches while considering patient-specific factors in treatment selection.

Al-Ola Abdallah, MD; Muhammad Umair Mushtaq, MD; Jeries Kort, MD; and Zahra Mahmoudjafari examine the evolving landscape of chimeric antigen receptor (CAR) T-cell therapy in earlier lines of treatment for relapsed/refractory multiple myeloma, exploring institutional challenges around patient selection, slot availability, referral processes, and decision-making frameworks while considering both clinical and practical factors that influence treatment sequencing and access.

Panelists discuss how emerging treatment strategies, including novel induction therapies, maintenance regimens, and bispecific antibodies, are reshaping the management of newly diagnosed and relapsed/refractory multiple myeloma, with insights from ASH 2024 data and ongoing trials.

Panelists discuss how the evolving landscape of targeted therapies for PIK3CA-mutated HR+ HER2- breast cancer, including the approval of inavolisib and the growing importance of biomarker testing, is reshaping treatment strategies, patient care, and adverse event management.

Alfred Garfall, MD; Omar Nadeem, MD; Naresh Bumma, MD; and Surbhi Sidana, MD,explore the evolving therapeutic landscape of relapsed/refractory multiple myeloma, including bispecific antibodies, real-world outcomes across treatment settings, optimal sequencing strategies after CAR T progression, and long-term efficacy data from key clinical trials like MajesTEC-1.

Saad Usmani, MD, MBA; Carlyn Rose Tan, MD; Sham Mailankody, MBBS, and Sridevi Rajeeve, MD, examine evolving chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma, discussing recent clinical trial data for cilta-cel and ide-cel, comparing study outcomes, evaluating institutional implementation factors, and assessing patient eligibility criteria for optimal therapy selection in earlier treatment lines.

Panelists discuss how the introduction of bispecific antibodies is transforming the treatment landscape for relapsed/refractory multiple myeloma, addressing unmet needs and improving patient outcomes through innovative combination strategies and sequencing approaches.

Medical experts explore the optimization of patient referrals for bispecifics and CAR-T therapies through academic and community collaborations, addressing referral processes, challenges, and practical strategies with insights.

Medical experts offer insights on distinguishing RCC renal cell carcinoma (RCC) subtypes, evolving treatments, and personalized strategies for advanced non–-clear cell RCC.

A panel of experts on chronic myeloid leukemia have a comprehensive discussion on patient-centered care and the important role of shared decision-making in the optimal treatment of patients with CML.

This program was made possible with support from Novartis Pharmaceuticals.

Key opinion leaders explore the integration of circulating tumor DNA and minimal residual disease assessments into clinical practice for colorectal cancer management, discussing current applications and future prospects.

Following the 2024 ASCO Annual Meeting, a panel of experts on multiple myeloma review recent updates and discuss evolving treatment practices.

A panel of medical oncologists have a comprehensive discussion on MRD testing and the utility of ctDNA in the management of colorectal cancer, highlighting clinical trial updates from ASCO GI 2024.